{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:07:52Z","timestamp":1792390072515,"version":"4.4.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.cell.2021.05.005","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T14:15:23Z","timestamp":1622038523000},"page":"3086-3108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":364,"title":["Tackling COVID-19 with neutralizing monoclonal antibodies"],"prefix":"10.1016","volume":"184","author":[{"given":"Davide","family":"Corti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Snell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Veesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2021.05.005_bib1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19","volume":"384","author":"Lundgren","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00694-18","article-title":"Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza","volume":"62","author":"Ali","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cell.2021.05.005_bib3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.4049\/jimmunol.2000583","article-title":"A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection","volume":"205","author":"Alsoussi","year":"2020","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.cell.2021.05.005_bib4","article-title":"SARS-CoV-2 escape in\u00a0vitro from a highly neutralizing COVID-19 convalescent plasma","author":"Andreano","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib7","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib10","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib12","series-title":"Ueber das Zustandekommen der Diphtherie-Immunit\u00e4t und der Tetanus-Immunit\u00e4t bei Thieren","author":"Behring","year":"2013"},{"key":"10.1016\/j.cell.2021.05.005_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","article-title":"Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection","volume":"588","author":"Bournazos","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cell.2021.05.005_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.abe9728","article-title":"Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic","volume":"371","author":"Buss","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients\u2019 B Cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib18","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1542\/peds.2008-1036","article-title":"Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial","volume":"125","author":"Carbonell-Estrany","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.cell.2021.05.005_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib20","article-title":"The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in\u00a0vitro and in\u00a0vivo activity against SARS-CoV-2","author":"Cathcart","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib21","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite","volume":"29","author":"Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2021.05.005_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib24","article-title":"In\u00a0vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains","author":"Chen","year":"2021","journal-title":"Research Square"},{"key":"10.1016\/j.cell.2021.05.005_bib25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib27","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host","volume":"383","author":"Choi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abf6840","article-title":"Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice","volume":"371","author":"Cohen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib30","article-title":"In\u00a0vitro and in\u00a0vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans","author":"Copin","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib31","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.coviro.2017.03.002","article-title":"Tackling influenza with broadly neutralizing antibodies","volume":"24","author":"Corti","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.cell.2021.05.005_bib33","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences","volume":"169","author":"Dall\u2019Acqua","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.cell.2021.05.005_bib34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1126\/science.abd3072","article-title":"Neuropilin-1 is a host factor for SARS-CoV-2 infection","volume":"370","author":"Daly","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","article-title":"Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7","volume":"593","author":"Davies","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.04.025","article-title":"Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant","author":"Deng","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib39","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4161\/rna.8.2.15013","article-title":"Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity","volume":"8","author":"Denison","year":"2011","journal-title":"RNA Biol."},{"key":"10.1016\/j.cell.2021.05.005_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc\u03b3R interactions for protection against influenza virus in\u00a0vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib41","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in\u00a0vivo protection","volume":"126","author":"Dilillo","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2021.05.005_bib42","article-title":"Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail","author":"Dong","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib43","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-018-03665-3","article-title":"How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin","volume":"9","author":"Doud","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2021.05.005_bib44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","article-title":"Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy","volume":"183","author":"Du","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib45","series-title":"Emergency Use Authorization (EUA) for bamlanivimab. Center for Drug Evaluation and Research (CDER)","year":"2020"},{"key":"10.1016\/j.cell.2021.05.005_bib46","series-title":"FACT SHEET FOR HEALTH CARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF CASIRIVIMAB AND IMDEVIMAB. Emergency Use Authorization","year":"2020"},{"key":"10.1016\/j.cell.2021.05.005_bib47","series-title":"Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID 19 Public Health Emergency","year":"2021"},{"key":"10.1016\/j.cell.2021.05.005_bib48","article-title":"A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain core","author":"Fedry","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00170-5","article-title":"Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study","author":"Frampton","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cell.2021.05.005_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/14712590802610692","article-title":"Palivizumab: where to from here?","volume":"9","author":"Georgescu","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.cell.2021.05.005_bib51","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2021.05.005_bib52","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2468-2667(21)00055-4","article-title":"Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study","volume":"6","author":"Graham","year":"2021","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.cell.2021.05.005_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2021.05.005_bib54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","article-title":"Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2021.05.005_bib55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib56","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib161","article-title":"Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab","author":"Gupta","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib57","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib58","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cell.2021.05.005_bib59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"Hessell","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib60","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","article-title":"Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1","volume":"75","author":"Hezareh","year":"2001","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.cell.2021.05.005_bib160","article-title":"SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination","author":"Hoffmann","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib61","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib62","article-title":"SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination","author":"Hoffmann","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib63","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial","author":"Horby","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.cell.2021.05.005_bib65","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 - Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib66","doi-asserted-by":"crossref","first-page":"eabf1906","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates","volume":"13","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101475","article-title":"Broadly neutralizing antibodies for HIV-1 prevention and therapy","author":"Julg","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.cell.2021.05.005_bib69","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib70","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","article-title":"Structures and distributions of SARS-CoV-2 spike proteins on intact virions","volume":"588","author":"Ke","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","article-title":"Developing therapeutic monoclonal antibodies at pandemic pace","volume":"38","author":"Kelley","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cell.2021.05.005_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3139","article-title":"Process and operations strategies to enable global access to antibody therapies","author":"Kelley","year":"2021","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.cell.2021.05.005_bib73","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib74","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.cell.2021.05.005_bib75","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41467-020-20602-5","article-title":"A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein","volume":"12","author":"Kim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2021.05.005_bib76","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.1038\/s41598-018-28706-1","article-title":"The influenza virus hemagglutinin head evolves faster than the stalk domain","volume":"8","author":"Kirkpatrick","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cell.2021.05.005_bib77","first-page":"237","article-title":"SARS-CoV-2 structure and replication characterized by in\u00a0situcryo-electron tomography","volume":"3","author":"Klein","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2021.05.005_bib78","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced neonatal Fc receptor function improves protection against primate SHIV infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib79","article-title":"Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals","author":"Kustin","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib80","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.cell.2021.05.005_bib81","article-title":"Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies","author":"Lempp","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib82","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.cell.2021.05.005_bib83","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib84","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00352-20","article-title":"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection","volume":"64","author":"Lim","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cell.2021.05.005_bib85","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMc2102017","article-title":"Neutralizing Activity of BNT162b2-Elicited Serum","volume":"384","author":"Liu","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib86","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","article-title":"Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization","volume":"29","author":"Liu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cell.2021.05.005_bib87","article-title":"The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated with Convalescent Plasma","author":"Ma","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.cell.2021.05.005_bib89","article-title":"SARS-CoV-2 immune evasion by variant B.1.427\/B.1.429","author":"McCallum","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib90","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"McCallum","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib91","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.abf6950","article-title":"Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape","volume":"371","author":"McCarthy","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib92","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib93","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib94","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib95","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib96","doi-asserted-by":"crossref","first-page":"100264","DOI":"10.1016\/j.xcrm.2021.100264","article-title":"BNT162b2 Vaccination Effectively Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in high risk populations in Israel","volume":"2","author":"Munitz","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib97","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41591-019-0463-x","article-title":"Novel correlates of protection against pandemic H1N1 influenza A virus infection","volume":"25","author":"Ng","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib98","series-title":"Statement\u2014NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies","year":"2021"},{"key":"10.1016\/j.cell.2021.05.005_bib99","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1107\/S0907444908007877","article-title":"Structural characterization of a human Fc fragment engineered for lack of effector functions","volume":"64","author":"Oganesyan","year":"2008","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.cell.2021.05.005_bib100","doi-asserted-by":"crossref","first-page":"365ra158","DOI":"10.1126\/scitranslmed.aaf9418","article-title":"Elucidating the interplay between IgG-Fc valency and Fc\u03b3R activation for the design of immune complex inhibitors","volume":"8","author":"Ortiz","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib101","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.abe5901","article-title":"Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans","volume":"371","author":"Oude Munnink","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib102","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib103","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib104","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib105","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41564-020-0770-5","article-title":"A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology","volume":"5","author":"Rambaut","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.cell.2021.05.005_bib106","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.abf4830","article-title":"Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody","volume":"371","author":"Rappazzo","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib107","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM191912111812406","article-title":"Treatment of Influenza-Pneumonia by Use of Convalescent Human Serum","volume":"181","author":"Redden","year":"1919","journal-title":"Boston Med. Surg. J."},{"key":"10.1016\/j.cell.2021.05.005_bib108","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib109","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent antibody responses to SARS-CoV-2 in convalescent individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib110","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib111","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib112","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1016\/j.ygeno.2020.11.003","article-title":"Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the novel coronavirus","volume":"112","author":"Roy","year":"2020","journal-title":"Genomics"},{"key":"10.1016\/j.cell.2021.05.005_bib113","article-title":"Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant","author":"Ryu","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib114","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(21)00183-5","article-title":"Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence","volume":"397","author":"Sabino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cell.2021.05.005_bib115","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00705-020-04911-0","article-title":"Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations","volume":"166","author":"Sarkar","year":"2021","journal-title":"Arch. Virol."},{"key":"10.1016\/j.cell.2021.05.005_bib116","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1084\/jem.20201993","article-title":"Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in\u00a0vivo","volume":"218","author":"Sch\u00e4fer","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib117","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","article-title":"HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1","volume":"352","author":"Schoofs","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib118","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib119","first-page":"946","article-title":"Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants","volume":"390","author":"Sim\u00f5es","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cell.2021.05.005_bib120","article-title":"The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN","author":"Soh","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib121","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib122","article-title":"Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape","author":"Starr","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib123","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib124","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.xcrm.2021.100255","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.cell.2021.05.005_bib125","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","article-title":"Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein","volume":"184","author":"Suryadevara","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib126","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2021.05.005_bib127","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-021-01255-3","article-title":"Sixteen novel lineages of SARS-CoV-2 in South Africa","volume":"27","author":"Tegally","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib128","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cell.2021.01.037","article-title":"Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity","volume":"184","author":"Thomson","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.cell.2021.05.005_bib130","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib131","article-title":"Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody","author":"Tortorici","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib132","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijid.2021.02.054","article-title":"Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients: propensity-score matched case-control study","volume":"105","author":"Tworek","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cell.2021.05.005_bib133","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cell.2020.11.020","article-title":"Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity","volume":"184","author":"Volz","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib134","article-title":"Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma","author":"Voss","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature16988","article-title":"Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer","volume":"531","author":"Walls","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib136","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib137","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib138","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib139","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cell.2021.05.005_bib140","article-title":"Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization","author":"Wang","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.cell.2021.05.005_bib141","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib142","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib143","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","article-title":"Broad neutralization of SARS-related viruses by human monoclonal antibodies","volume":"369","author":"Wec","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib144","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib145","doi-asserted-by":"crossref","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.cell.2021.05.005_bib146","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1172\/JCI128437","article-title":"Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways","volume":"129","author":"Weitzenfeld","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2021.05.005_bib147","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib148","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2021.05.005_bib149","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib150","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib151","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/cimm.2000.1617","article-title":"In\u00a0vitro characterization of five humanized OKT3 effector function variant antibodies","volume":"200","author":"Xu","year":"2000","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cell.2021.05.005_bib153","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cell.2021.05.005_bib154","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in\u00a0vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cell.2021.05.005_bib155","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.virol.2003.10.018","article-title":"Respiratory syncytial virus escape mutant derived in\u00a0vitro resists palivizumab prophylaxis in cotton rats","volume":"318","author":"Zhao","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.cell.2021.05.005_bib156","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cell.2021.05.005_bib157","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and\/or motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.cell.2021.05.005_bib158","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2021.05.005_bib159","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"}],"updated-by":[{"DOI":"10.1016\/j.cell.2021.07.027","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000}}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867421006024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867421006024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:53:34Z","timestamp":1758801214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867421006024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":160,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0092867421006024"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2021.05.005","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tackling COVID-19 with neutralizing monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2021.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}